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The important pathological consequences of ischaemic heart disease arise from the detrimental effects of the accumulation of
long-chain acylcarnitines in the case of acute ischaemia-reperfusion. The aim of this study is to test whether decreasing the
L-carnitine content represents an effective strategy to decrease accumulation of long-chain acylcarnitines and to reduce fatty
acid oxidation in order to protect the heart against acute ischaemia–reperfusion injury.
KEY RESULTS
In this study, we used a novel compound, 4-[ethyl(dimethyl)ammonio]butanoate (Methyl-GBB), which inhibits γ-butyrobetaine
dioxygenase (IC50 3 μM) and organic cation transporter 2 (OCTN2, IC50 3 μM), and, in turn, decreases levels of L-carnitine
and acylcarnitines in heart tissue. Methyl-GBB reduced both mitochondrial and peroxisomal palmitate oxidation rates by 44
and 53% respectively. In isolated hearts treated with Methyl-GBB, uptake and oxidation rates of labelled palmitate were
decreased by 40%, while glucose oxidation was increased twofold. Methyl-GBB (5 or 20 mg·kg−1) decreased the infarct size
by 45–48%. In vivo pretreatment with Methyl-GBB (20 mg·kg−1) attenuated the infarct size by 45% and improved 24 h
survival of rats by 20–30%.
CONCLUSIONS AND IMPLICATIONS
Reduction of L-carnitine and long-chain acylcarnitine content by the inhibition of OCTN2 represents an effective strategy to
protect the heart against ischaemia–reperfusion-induced damage. Methyl-GBB treatment exerted cardioprotective effects and
increased survival by limiting long-chain fatty acid oxidation and facilitating glucose metabolism.
Abbreviations
AAR, area at risk; ACOX, acyl-CoA oxidase 1; ACSL, long-chain fatty acid CoA synthetase; AN, area of necrosis; BBOX,
γ-butyrobetaine dioxygenase; CD36, fatty acid translocase; CPT I, carnitine palmitoyltransferase I; FABP, fatty acid
binding protein; FAO, fatty acid oxidation; HR, heart rate; IHD, ischaemic heart disease; IS, infarct size; KH,
Krebs-Henseleit; LAD, left anterior descending coronary artery; LCFA, long-chain fatty acids; LV, left ventricle; LVDP,
left ventricle developed pressure; Methyl-GBB, 4-[ethyl(dimethyl)ammonio]butanoate; OCTN2, organic cation
transporter 2; PGC-1α, PPAR-γ coactivator 1α; TTC, 2,3,5-triphenyltetrazolium chloride
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Introduction
Ischaemic heart disease (IHD) is a major medical problem
causing disability and death for millions of people annually
(Lavie et al., 2009). The important pathological consequences
of IHD arise from the detrimental effects of the accumulation
of long-chain fatty acids (LCFAs) in the case of acute
ischaemia-reperfusion (Wang and Lopaschuk, 2007; Liepinsh
et al., 2013b). Therefore, pharmacological intervention that
targets LCFA accumulation has been suggested for the devel-
opment of novel treatment strategies to improve the clinical
outcomes of patients with IHD (Horowitz et al., 2010;
Lopaschuk et al., 2010). The main advantages of reduced
LCFA oxidation are the reduction of energy waste through
mitochondrial uncoupling induced by LCFA overload as well
as the reduction of direct damage by LCFA metabolites on
glucose metabolism and insulin signalling (Zhang et al.,
2011). In addition, pharmacological manipulation of energy
metabolism does not directly influence the haemodynamic
parameters of the heart and could be combined with existing
cardiovascular therapies.
LCFAs supply a major part of the energy that is required
for heart function (Wang and Lopaschuk, 2007). However,
under conditions of ischaemia-reperfusion, a reduced use of
fatty acids and a greater use of glucose oxidation as the energy
source lead to better functional recovery of the myocardium.
Carnitine palmitoyltransferase I (CPT I) is the most important
rate-limiting step in LCFA uptake and oxidation by mitochon-
dria (Sebastian et al., 2009; Shriver and Manchester, 2011).
L-carnitine is a cofactor required by CPT I-dependent LCFA
transport, and a decreased cardiac content of L-carnitine
limits LCFA oxidation in heart mitochondria (Liepinsh et al.,
2011a; Kuka et al., 2012). Decreased availability of L-carnitine
can be achieved by the administration of 3-(2,2,2-
trimethylhydrazinium)-propionate (meldonium) (Liepinsh
et al., 2011a,b). As a result of decreased L-carnitine content
and inhibited CPT I-dependent LCFA oxidation, an increase
in glucose oxidation was observed. Thus, several studies dem-
onstrate that a long-term decrease in L-carnitine availability is
beneficial for the regulation of energy metabolism and treat-
ment of heart diseases and atherosclerosis (Liepinsh et al.,
2006; 2009; 2011c; Vilskersts et al., 2009; Kuka et al., 2012)
In this study, we describe a novel compound, 4-[ethyl
(dimethyl)ammonio]butanoate (Methyl-GBB) (Kalvinsh
et al., 2011), which is more potent than meldonium as an
inhibitor of γ-butyrobetaine dioxygenase (BBOX) and the
organic cation transporter 2 (OCTN2) and significantly
decreases L-carnitine content in heart tissue. To determine
the effects of Methyl-GBB on LCFA and glucose oxidation, we
measured the oxidation rate of labelled palmitate and glucose
in isolated hearts. Taking into account previous concerns
about heart functional alterations in models of genetically or
pharmacologically decreased fatty acid metabolism, we per-
formed measurements of heart function in isolated heart
perfusions along with in vivo echocardiography. To evaluate
the cardioprotective properties of Methyl-GBB, we measured
infarct size (IS) in isolated hearts and in vivo. The purpose of
the current study was to test whether decreasing L-carnitine
content represents an effective strategy to protect the heart
against the injury induced by acute ischaemia–reperfusion.
Methods
Animals and treatment
All animal care and experimental procedures complied with
the guidelines of the European Community and local laws
and policies and were approved by the Latvian Animal Pro-
tection Ethical Committee, Food and Veterinary Service, Riga,
Latvia. Studies involving animals are reported in accordance
with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath
et al., 2010). A total of 92 animals were used in the experi-
ments described here.
Eighty male Wistar rats weighing 250–300 g were housed
under standard conditions (21–23°C, 12 h light-dark cycle)
with unlimited access to food (R70 diet, Lantmännen Lant-
bruk, Malmö, Sweden) and water. Twelve male ICR mice
weighing 25–28 g were housed under standard conditions
(21–23°C, 12 h light-dark cycle) with unlimited access to food
(R70 diet) and water. Animals (rats and mice) were obtained
from the Laboratory of Experimental animals, Riga Stradins
University (Riga, Latvia). The rats were adapted to local con-
ditions for 2 weeks before the start of treatment. Methyl-GBB
at doses of 1, 5, 10 and 20 mg·kg−1 was administered p.o. by
gavage daily for 3–14 days. Meldonium was administered at
a dose of 100 mg·kg−1 for 14 days. Control rats received
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Group sizes were selected according to previous experi-
ence or pilot experiments. According to the animal welfare
‘reduction’ principle, we used the minimal number of
animals to reach statistical significance. Rats were rand-
omized before the beginning of treatment. In vivo and ex vivo
myocardial infarction experiments were performed without
knowledge of the treatments, by both surgeon and researcher
who measured IS by planimetric analysis.
Measurement of levels of L-carnitine,
Methyl-GBB and acylcarnitines by
UPLC/MS/MS
Determination of L-carnitine and Methyl-GBB in heart tissue,
plasma and urine samples was performed by ultra-
performance liquid chromatography-tandem mass spectrom-
etry (UPLC/MS/MS) using the positive ion electrospray mode.
The previously described UPLC/MS/MS method (Dambrova
et al., 2008) was slightly modified. Determination of the acyl-
carnitines in the mitochondrial and heart tissue samples was
performed by UPLC/MS/MS method (Makrecka et al., 2014).
The sample preparation was performed as previously
described (Blachnio-Zabielska et al., 2011) with modifications
(Liepinsh et al., 2013b). The concentrations of acylcarnitines
were measured using a 7-point standard curve of palmitoyl-
carnitine (10–1000 ng·mL−1).
Mitochondrial and peroxisomal fatty acid
oxidation (FAO)
The mitochondrial and peroxisomal rates of palmitate oxida-
tion were determined as described previously (Degrace et al.,
2004), with the exception being that corresponding concen-
trations of L-carnitine were used. The reaction was started by
the addition of 100 μM palmitate (supplemented with 1 μCi
[1-14C]palmitate, specific activity 60 Ci·mmol−1) bound to
fatty-acid-free BSA. After 60 min of incubation at 37°C, the
samples were treated with 10% perchloric acid. To measure
peroxisomal palmitate oxidation, the mitochondrial
β-oxidation activity was inhibited by preincubating the
samples with 75 μM antimycin, 10 μM rotenone and 250 μM
KCN. The rate of peroxisomal palmitate oxidation was calcu-
lated from the radioactivity of the acid-soluble products and
was expressed as pmol of palmitate per min per mg protein.
The rate of mitochondrial palmitate oxidation was expressed
as the difference between total palmitate oxidation (without
inhibitors) and peroxisomal oxidation rate.
Measurements of substrate oxidation in rat
isolated heart
The rates of radiolabelled glucose, lactate and palmitate oxi-
dation were measured in different sets of hearts from Wistar
rats, as previously described (Lopaschuk and Barr, 1997), with
certain modifications indicated below. The energy metabo-
lism measurements were performed according to the Langen-
dorff perfusion technique. The hearts were retrogradely
perfused (perfusion pressure 70 mmHg) with Krebs-Henseleit
(KH) buffer solution ‘high insulin’ supplemented with
10 mM glucose, 0.3 mM sodium palmitate bound to 2% BSA,
2 mM lactate, 0.2 mM pyruvate and 3 ng·mL−1 insulin, or
with KH buffer solution ‘low insulin’ supplemented with
5 mM glucose, 1.2 mM sodium palmitate bound to 2% BSA,
1 mM lactate, 0.1 mM pyruvate and 0.3 ng·mL−1 insulin.
After 10 min, the perfusate was switched to the respective
(‘high’ or ‘low insulin’) oxygenated radiolabelled KH buffer
solution for 10 min at a constant flow of 10 mL·min−1. Then
the hearts were switched back to the respective non-labelled
KH perfusion solution and perfused for 10 min at the con-
stant flow prior to the global ischaemia. Global no-flow
ischaemia was induced for 20 min followed by 60 min
reperfusion. At the end of the reperfusion, the perfusate
was switched to the respective (‘high’ or ‘low insulin’) oxy-
genated radiolabelled KH buffer solution for 10 min at a
constant flow of 10 mL·min–1. Glucose and lactate oxidation
rates were determined by measuring the 14CO2 released
from the metabolism of [U-14C]glucose (specific activity,
300 mCi·mmol−1) or [1-14C] lactate (specific activity,
55 mCi·mmol−1) respectively. Palmitate oxidation was deter-
mined by measuring 3H2O released from [9,10-3H]palmitate
(specific activity, 60 Ci·mmol−1). Palmitate uptake in the heart
was calculated from the amount of radiolabelled palmitate
oxidized during the perfusion and the amount found in the
cardiac tissue at the end of the perfusion.
Measurements of palmitate uptake and
oxidation in vivo
To determine the palmitate uptake and oxidation in vivo,
1 μCi of [9,10-3H]palmitate (specific activity, 60 Ci·mmol−1)
per 25 g of body weight was administered intravenously to
the mice. After 10 min, the mice were killed by cervical dis-
location, and heart and muscle tissue homogenates (1:5, w/v
in Milli-Q water) were prepared. Samples were treated in the
same manner as in the isolated heart experiment.
Mitochondrial respiration measurements
The mitochondria were isolated from cardiac tissues, and
mitochondrial respiration was measured at 37°C using a
Clark-type electrode (Microelectrodes Inc., Bedford, MA,
USA) as previously described (Kuka et al., 2012). To determine
the L-carnitine-dependent oxidation of fatty acids, 10 μM
palmitoyl-CoA and specified L-carnitine concentrations were
used for the respiration measurements. Palmitoylcarnitine
(10 μM) was used as a substrate to determine L-carnitine-
independent FAO.
To assess mitochondrial function after ischaemia-
reperfusion injury, rat isolated hearts were subjected to
20 min of no-flow ischaemia following 120 min reperfusion,
and then cardiac fibres were prepared as previously described
(Kuka et al., 2012). Respiration rates of cardiac fibres were
measured at 37°C with Clark-type electrode using 6 mM
pyruvate/6 mM malate as substrates. ADP-stimulated respira-
tion (state 3) was achieved by adding 0.2 mM ADP. To deter-
mine the uncoupling of oxidative phosphorylation, state 4
respiration was measured after the addition of 5 μM carboxy-
atractyloside.
mRNA isolation and quantitative RT-PCR
Total RNA from heart tissue in normoxia and after 30 min of
no-flow ischaemia followed by 60 min reperfusion was iso-
lated using the TRI Reagent (Sigma, St. Louis, MO, USA)
according to the manufacturer’s protocol. First-strand cDNA
was synthesized using a High Capacity cDNA Reverse
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Transcription Kit (Applied BiosystemsTM, Foster City, CA,
USA) following the manufacturer’s instructions. Quantitative
RT-PCR analysis for genes was performed by mixing synthe-
sized cDNA, forward and reverse primers specific for long-
chain fatty acid CoA synthetase (ACSL), CPT1A, CPT1B, acyl-
CoA oxidase (ACOX), fatty acid translocase (CD36), FABP and
β-actin, and SYBR® Green Master Mix (Applied Biosystems),
and run in the Applied Biosystems Prism 7500 according to
the manufacturer’s protocol. The transcript levels for the
constitutive housekeeping gene product β-actin were quanti-
tatively measured for each sample, and RT-PCR data were
reported as the number of transcripts per number of β-actin
mRNA molecules. To avoid genomic DNA contamination, the
primers were designed to span an intron. The primer
sequences used for the quantitative RT-PCR analysis are listed
in Supporting Information Table S1.
Rat isolated heart infarction study
The infarction was performed according to the Langendorff
technique as described previously (Kuka et al., 2012), with
some modifications. For the infarction studies, the hearts
were perfused with KH buffer solution at a constant perfusion
pressure of 60 mmHg. The isolated hearts were allowed to
stabilize for 20 min, and the left anterior descending coro-
nary artery (LAD) was subsequently occluded for 40 min fol-
lowed by 120 min of reperfusion. Occlusion was confirmed
by the 40% drop in coronary flow. The IS was determined as
described previously (Kuka et al., 2012; Liepinsh et al.,
2013a). Briefly, at the end of the reperfusion, the LAD was
re-occluded, and the heart was perfused with 0.1% methylene
blue dissolved in KH buffer solution. Afterwards, the ventri-
cles of the heart were transversely cut into 2-mm-thick slices
stained by 2,3,5-triphenyltetrazolium chloride (TTC) and
photographed. Computerized planimetric analyses of the
stained ventricle slice photographs were performed using
Image-Pro Plus v6.3 (Media Cybernetics) software to deter-
mine the area at risk (AAR) and the area of necrosis (AN), and
each area was expressed as a percentage of the left ventricle
area. The obtained values were then used to calculate the IS as
a percentage of the risk area, according to the formula IS =
AN/AAR × 100%.
Heart infarction study in vivo
Before evaluation of Methyl-GBB in our experimental model
of LAD occlusion and reperfusion in vivo, we validated this
model. In the control group, the IS values were more variable
after 20 min, than after 30 min of occlusion and we therefore
chose a 30 min occlusion period for further experiments. As
mentioned by Hearse et al. (1988), at least several hours are
necessary for development of necrosis after occlusion. There-
fore, in our experiments, we chose to reperfuse 24h after
occlusion to ensure that all the damaged tissue was meas-
ured. Several studies have used the same procedure: 30 min
occlusion of the LAD followed by 24 h reperfusion (Deuchar
et al., 2007; Mohan et al., 2009; Ertracht et al., 2011). In con-
trast to Hearse et al. (1988), we observed very minor wall
thinning after 24 h of reperfusion in both control and treat-
ment groups. We could confirm the positive staining for
leukocytes (with TTC) in the AN, as observed by Hearse.
However, in properly processed high-quality digital photo-
micrographs, this staining is pale pink to pink and differs
substantially from viable red to dark red tissue (Liepinsh
et al., 2013a).
Before the induction of anaesthesia, experimental
animals received s.c. injections of atropine sulfate
(50 μg·kg−1), tramadol (20 mg·kg−1) and sodium benzylpeni-
cillin (150 mg·kg−1).
Anaesthesia was induced by i.p. injection of a mixture of
ketamine and xylazine (100 and 10 mg·kg−1 respectively).
After the loss of nociceptive reflexes, the experimental
animals were intubated using 16G intravenous catheters
(Venflon, Becton Dickinson, Franklin Lakes, NJ, USA),
ventilated with room air by a UB 7025 rodent ventilator
(Hugo Sachs Elektronik-Harvard Apparatus GmbH, March-
Hugstetten, Germany) at a tidal volume of 1.5 mL/100 g
animal and a rate of 55 strokes per minute. The chest was
opened between ribs 5 and 6, a 5-0 polypropylene thread
(SURGIPRO™ II; Covidien, Dublin, Ireland) was placed
around the left coronary artery at the level of the left atrium,
and a polypropylene ligature was passed through a piece of
plastic tubing. The ECG was recorded from a standard lead (II)
using PowerLab systems (ADInstruments, Oxford, UK). After
surgery, the experimental animals were allowed to stabilize for
10 min. The coronary artery was occluded by applying
tension to the plastic tube-polypropylene string arrangement.
Successful occlusion was confirmed by ischaemia-induced
alterations in the ECG. After 30 min of occlusion, reperfusion
was initiated by removing the clamp from the plastic tube.
Afterwards, the chest was closed using 3-0 silk threads
(SOFSILK II; Covidien), and the skin was closed using 4-0
nylon threads (MONOSOF; Covidien). When the animals
started to breathe spontaneously, they were extubated.
Twenty-four hours following the induction of reperfu-
sion, the experimental animals received an i.p. injection
of sodium pentobarbital (60 mg·kg−1) and heparin
(1000 IU·kg−1). After the onset of anaesthesia, the heart
was excised, connected via the aorta to the Langendorff appa-
ratus and washed with KH buffer solution. The coronary
artery was re-occluded; staining and quantification of
necrotic tissues were performed as in an isolated heart infarc-
tion set-up.
Data analysis
Results are presented as the mean ± SEM. Statistically signifi-
cant differences in the mean values were evaluated using an
unpaired Student’s t-test, chi-square test or a one-way ANOVA
with Tukey’s test. The differences were considered significant
when P < 0.05. The data were analysed using GraphPad Prism
3 statistical software (GraphPad Inc., La Jolla, CA, USA).
Materials
Methyl-GBB was synthesized according to the method
described previously (Kalvinsh et al., 2011; Tars et al., 2014).
Meldonium was a kind gift from JSC Grindeks, Riga, Latvia.
[U-14C]glucose, [1-14C]palmitate, [9,10-3H]palmitate and
[1-14C]lactate were supplied by American Radiolabeled
Chemicals, St. Louis, USA. Antimycin, carboxyatractyloside,
L-carnitine, rotenone and sodium palmitate were from
Sigma-Aldrich, St. Louis, USA. Palmitoylcarnitine and
palmitoyl-CoA were from Larodan, Malmo, Sweden.
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Results
Content of L-carnitine in heart, blood plasma
and urine
The effects of Methyl-GBB on the L-carnitine system can be
explained by inhibition of BBOX and OCTN2 (Table 1). In
comparison to meldonium, Methyl-GBB was eight times
more potent than meldonium at inhibiting L-carnitine syn-
thesis by BBOX (IC50 3 μM vs. 26 μM) and 20 times more
potent at inhibiting L-carnitine transport by OCTN2 (IC50
3 μM vs. 62 μM) (Liepinsh et al., 2014). The plasma concen-
trations of Methyl-GBB reached their highest values after 3–7
days of treatment and remained unchanged for the remain-
der of the 14 day treatment (Supporting Information Fig. S2).
After 3 days of the treatment at doses of 5 and 20 mg·kg−1,
plasma concentration of Methyl-GBB exceeded 10 μM and
according to measurements in vitro (Supporting Information
Fig. S1) almost completely inhibited L-carnitine transport by
OCTN2. Methyl-GBB not only inhibits carnitine transport by
OCTN2, but is also itself transported by OCTN2. Therefore, a
high affinity of methyl-GBB for OCTN2 ensures that methyl-
GBB has excellent bioavailability in tissues. After the 14 day
treatment at doses of 1, 5 and 20 mg·kg−1, Methyl-GBB con-
centrations in the heart were 47, 185 and 221 nmol·g−1
respectively (Figure 1A). The concentration of Methyl-GBB in
the heart increased in a time-dependent manner (Figure 1B),
reaching a maximum after 14 days of treatment. We previ-
ously found that to induce significant changes in energy
metabolism, the L-carnitine content in heart tissue should be
decreased by at least 60% (Kuka et al., 2012). As shown in
Figure 1A, treatment with meldonium for 2 weeks at a dose of
100 mg·kg−1 induced a significant decrease in the L-carnitine
heart content by 75%. In comparison, Methyl-GBB treatment
at 1, 5 and 20 mg·kg−1 decreased the L-carnitine content in
the heart by 42, 84 and 95% respectively.
To study the time-dependent effects of Methyl-GBB on
L-carnitine content, we measured the concentration of
L-carnitine in plasma samples after 1, 3, 7 and 14 day admin-
istrations of Methyl-GBB at a dose of 5 mg·kg−1. As shown in
Figure 1B, Methyl-GBB decreased L-carnitine content in the
heart in a time-dependent manner. Meanwhile, after short-
term (up to 7 days) treatment with Methyl-GBB, the blood
plasma concentration of L-carnitine did not correlate with
the changes in L-carnitine content in the heart (Figure 1B and
D). Thus, in contrast to the effects of Methyl-GBB on
L-carnitine content in the heart, a maximal reduction of
plasma L-carnitine concentration was observed only after 14
days of the treatment. Unexpectedly, Methyl-GBB (1 mg·kg−1)
did not decrease L-carnitine concentration in blood plasma
even after 14 days of treatment, while in heart tissue, a
significant reduction in L-carnitine content was observed
(Figure 1A and C). Furthermore, as a result of the OCTN2
inhibition, Methyl-GBB significantly increased the
L-carnitine concentration in urine (Figure 1E).
Content of acylcarnitines in heart
In Methyl-GBB-treated hearts, the acylcarnitine content was
significantly decreased both in heart and mitochondria
(Figure 2A and B). Methyl-GBB treatment induced up to
50-fold reduction in the content of long-chain acylcarnitines.
Thus, the link between decrease in the content of L-carnitine
and preserved mitochondrial function during reperfusion is
related to decreased content of long-chain acylcarnitines.
LCFAs and glucose oxidation
To test the changes in energy metabolism induced by Methyl-
GBB treatment, we determined the amount of FAO in the
isolated heart and its organelles. Initially, we tested the effects
of Methyl-GBB on the metabolism of LCFAs in mitochondria
and peroxisomes. The treatment with Methyl-GBB signifi-
cantly reduced both mitochondrial and peroxisomal palmi-
tate oxidation rates by 44 and 53% respectively (Figure 3A).
To elucidate the role of decreased L-carnitine content in the
Table 1






















2.8 ± 0.6 3 ± 0.3
The IC50 values are presented as the mean ± SD of at least three independent experiments and are taken from Tars et al. (2014) and Liepinsh
et al. (2014).
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regulation of FAO, we measured both the L-carnitine-
dependent and L-carnitine-independent mitochondrial respi-
ration rates. After 14 days of Methyl-GBB treatment, the
L-carnitine-dependent mitochondrial respiration rate with
palmitoyl-CoA was decreased by 27% (Figure 3B), but the
treatment had no effect on the L-carnitine-independent
mitochondrial respiration rate with palmitoylcarnitine
(Figure 3C). We then determined the effects of Methyl-GBB
on the uptake and oxidation of LCFA in an isolated heart. In
contrast to the previously observed effects of meldonium
(Liepinsh et al., 2013b), the oxidation rate of labelled palmi-
tate in the isolated heart was decreased by 40% (Figure 4A).
An increase in LCFA oxidation was observed after reperfusion
in Methyl-GBB-treated group (Figure 4A). In addition, the
Methyl-GBB treatment reduced the labelled palmitate con-
centration in the mitochondria and, thus, also reduced the
risk of LCFA accumulation (Figure 4B). Additionally, we
measured the uptake and metabolism of labelled palmitate in
mice in vivo (Figure 4C). In hearts and skeletal muscle from
Methyl-GBB-treated mice, we observed a twofold decrease in
Figure 1
Content of L-carnitine, meldonium and Methyl-GBB in heart (A) and blood plasma (C), after 14 days of treatment by meldonium (100 mg·kg−1)
or Methyl-GBB (1, 5 and 20 mg·kg−1). Content of L-carnitine and Methyl-GBB in heart tissue (B) and blood plasma (D,) after 3, 7 and 14 days of
treatment by Methyl-GBB at a dose of 5 mg·kg–1. Effect of Methyl-GBB (5 mg·kg−1) on the L-carnitine content in urine after single administration
(E). Data shown are the means ± SEM of 5–10 animals. *P < 0.05, significantly different from control group; #P < 0.05, significantly different from
meldonium group; Tukey’s test.
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Figure 2
Effects of long-term treatment with Methyl-GBB (10 mg·kg−1) on cardiac (A) and mitochondrial (B) content of acylcarnitine. Data shown are the
means ± SEM of at least five animals. *P < 0.05, significantly different from control group; Student’s t-test.
Figure 3
Effects of long-term treatment with Methyl-GBB (10 mg·kg−1) on [1-14C]-palmitate oxidation in isolated mitochondria and peroxisomes (A) and
mitochondrial L-carnitine dependent respiration on 10 μM palmitoyl-CoA (B) and L-carnitine independent oxidation on 10 μM palmitoylcarnitine
(C). Data shown are the means ± SEM of five to six animals. *P < 0.05, significantly different from control group; Student’s t-test.
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the labelled palmitate uptake and oxidation rate, which coin-
cides with the results observed in the isolated heart and
organelles.
Treatment with Methyl-GBB induced a reduction in
LCFA oxidation and in turn stimulated glucose oxidation
(Figure 5A). Glucose oxidation was doubled in the Methyl-
GBB-treated isolated hearts perfused with low and high con-
centrations of insulin. Similarly, Methyl-GBB treatment
increased lactate uptake and oxidation rates in isolated hearts
(Figure 5B and C). Thus, Methyl-GBB treatment switched a
part of the energy production from LCFA to glucose
oxidation.
Expression of genes related to FAO
To detect the changes in the expression of the PPAR-α target
genes involved in LCFA metabolism, mRNA was isolated from
cardiac tissues in normoxia and after no-flow ischaemia
followed by reperfusion. Treatment with Methyl-GBB
(10 mg·kg−1) for 14 days had no effect on gene expression in
normoxia (data not shown), while it stimulated the expres-
sion of the genes related to LCFA uptake and metabolism in
the AAR after 60 min of reperfusion (Figure 6). On average,
long-term treatment with Methyl-GBB induced a 1.5- to 2.5-
fold increase in the expression of the genes involved in LCFA
uptake (CPT1A, CPT1B, FABP, CD36) and metabolism (ACSL,
ACOX). These results suggest that treatment with Methyl-
GBB activated the PPAR-α/PGC-1α signalling pathway
and stimulated the corresponding target genes, during
reperfusion.
Ex vivo and in vivo cardiac function
at baseline
To determine the functional consequences of Methyl-GBB
treatment under normal physiological conditions, we moni-
tored the function of isolated hearts before ischaemia and
performed echocardiography on anaesthetized rats. Measures
of systolic and diastolic functions were not altered after treat-
ment by Methyl-GBB (20 mg·kg−1). In fact, none of the vari-
ables measured were different between groups, including left
ventricular developed pressure, heart rate (HR), contraction,
relaxation and coronary flow in isolated heart and ejection
fraction, fractional shortening, isovolumic relaxation time
and E/A ratio in vivo (Figure 7 and Supporting Information
Figs S3 and S4). Consistent with unchanged cardiac function,
hearts from Methyl-GBB-treated rats had no structural or
morphological abnormalities: left ventricular internal diam-
eter in end diastole, left ventricular internal diameter in end
systole, interventricular septum thickness in diastole, inter-
ventricular septum thickness in systole, left ventricular pos-
terior wall thickness in diastole, left ventricular posterior wall
thickness in systole where unchanged (Supporting Informa-
tion Fig. S4). Together, these data indicate that despite
alterations in substrate metabolism, hearts from Methyl-GBB-
treated rats were neither functionally compromised nor had
any compensatory structural remodelling.
Infarction models in rat isolated heart and
in vivo
The anti-infarction effects of Methyl-GBB and meldonium
were investigated in both rat isolated hearts with in vitro
ischaemia-reperfusion, and in vivo. In rat isolated spontane-
ously beating hearts, these compounds did not affect HR,
peak left ventricle developed pressure (LVDP), coronary flow,
and LV contractility (+dp/dt) or LV relaxation (−dp/dt) either
before (Figure 7 and Supporting Information Fig. S3), during
or after ischaemia compared with the control group. During
Figure 4
Effects of long-term treatment with Methyl-GBB (10 mg·kg−1) on
[9,10-3H]-palmitate oxidation in isolated heart (A). In (B), mitochon-
drial [9,10-3H]-palmitate content is shown. In (C), results shown are
for free palmitate (FA) and for labelled acid-soluble metabolites in
heart and skeletal muscles in vivo. Data shown are the means ± SEM
of five to six animals. *P < 0.05, significantly different from control
group; Student’s t-test.
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LAD occlusion, the coronary flow in all experimental groups
was decreased by 39–44% and a fall in LVDP by 29–36% was
also observed. No changes in the HR during the occlusion
period were observed. In the reperfusion stage, coronary flow
recovered up to 77–87% of the baseline values. The values for
the AAR were similar in the hearts of all the experimental
groups, and the AAR was approximately 45–50% of the area
of the LV. As shown in Figure 8A, meldonium treatment
(100 mg·kg−1) decreased the IS by 25% (P = 0.03) of the
control group. Methyl-GBB (5 and 20 mg·kg−1) was more
effective and decreased the IS by 45–48%. Thus, Methyl-GBB
with a dose 20 times lower was almost twice as protective as
meldonium.
In earlier work, meldonium exhibited significant cardio-
protective effects only after 14 days of treatment (Liepinsh
et al., 2006). We therefore assessed the time-course of the
effects of Methyl-GBB. As shown in Figure 8B, after 7 days
of treatment, Methyl-GBB significantly decreased the IS by
24%. Overall, as seen with meldonium, long-term treat-
ment with Methyl-GBB was required to provide maximal
cardioprotection.
The ischaemia-reperfusion induced a 2.8-fold decrease in
state 3 respiration and a 40% increase in state 4 respiration
(Figure 8C and D). Methyl-GBB treatment protected against
the mitochondrial dysfunction induced by ischaemia-
reperfusion. Mitochondria respiration rate at state 3 was
increased by 50% compared with ischaemic control
(Figure 8C) and, for state 4 respiration, Methyl-GBB com-
pletely protected against ischaemia-reperfusion-induced
mitochondrial uncoupling (Figure 8D).
In the in vivo myocardial infarction model, the effects of a
14 day pretreatment with Methyl-GBB were evaluated. Values
of the AAR were comparable in all experimental groups
(Figure 9A). Pretreatment with Methyl-GBB (10 and
20 mg·kg−1) attenuated the IS by 18 and 45% (P = 0.001),
respectively, in Wistar rats undergoing LAD occlusion and
reperfusion in vivo (Figure 9B). Moreover, Methyl-GBB pre-
treatment improved the 24 h survival of rats by 20–30%
(Figure 9C). Thus, treatment with Methyl-GBB provided car-
dioprotective effects in isolated hearts ex vivo and in vivo.
Discussion
This study demonstrates that Methyl-GBB, a novel inhibitor
of BBOX and OCTN2, protected the myocardium from
ischaemia and reperfusion-induced damage in rat isolated
hearts and in vivo. Methyl-GBB effectively reduced content of
acylcarnitines in heart and mitochondria, limited LCFA oxi-
dation and, consequently, stimulated glucose oxidation in
Figure 5
Effects of long-term treatment with Methyl-GBB (10 mg·kg−1) on basal and insulin-stimulated [U-14C]-glucose oxidation (A) [1-14C], lactate uptake
(B) and oxidation (C) in isolated heart. Data shown are the means ± SEM of five to six animals. *P < 0.05, significantly different from control group;
Student’s t-test.
Figure 6
Effects of long-term treatment with Methyl-GBB (10 mg·kg−1) on
gene expression in reperfusion [ACSL, carnitine palmitoyltransferase
I, liver isoform (CPT-1A) and muscle isoform (CPT-1B), acyl-CoA
oxidase 1 (ACOX), fatty acid translocase (CD36), fatty acid binding
protein (FABP)]. mRNA isolated from rat heart tissue after 30 min
ischaemia/60 min reperfusion injury. Data shown are the means ±
SEM of eight animals. *P < 0.05, significantly different from control
group; Student’s t-test.
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the heart tissues by lowering L-carnitine availability. Despite
these significant changes in myocardial metabolism, no evi-
dence of cardiac dysfunction was observed in isolated hearts
ex vivo or by echocardiography in rats in vivo. Different
approaches have been used to partly inhibit LCFA oxidation
and switch energy metabolism from LCFA to glucose oxida-
tion (Lopaschuk et al., 1989; Kantor et al., 2000; Dyck et al.,
2004). CPT I is considered to be a rate-limiting enzyme for
LCFA transport into mitochondria and is often targeted to
achieve inhibition of LCFA metabolism (Lopaschuk et al.,
1989; Unger et al., 2005; Bentebibel et al., 2006). In addition
to the direct inhibition of CPT I or to an increase in malonyl-
CoA content, a decrease in L-carnitine concentration in heart
tissues was found to be one of the most effective ways to
decrease the activity of CPT I. For a long time, the only
non-toxic and effective compound that decreased the con-
centration of L-carnitine and consequently had protective
effects against cardiovascular diseases was meldonium
(Dambrova et al., 2002; Schurch et al., 2010). In comparison,
the new compound Methyl-GBB is 10–20 times more potent
as an inhibitor of BBOX and OCTN2, and it was more effec-
tive in reducing the L-carnitine concentration in blood
plasma and tissues. Thus, the same decrease of L-carnitine in
cardiac tissues was induced by Methyl-GBB at a dose 20 times
lower than that of meldonium. Previously, long-term meldo-
nium treatment was shown to decrease the plasma concen-
trations of L-carnitine through the inhibition of renal
re-uptake (Liepinsh et al., 2011b). Similarly, Methyl-GBB
increased L-carnitine content in the urine even after a few
hours of administration. This effect is attributed to a highly
efficient inhibition of OCTN2 which results in rapid
L-carnitine excretion. Overall, the decreased L-carnitine
content in tissues after Methyl-GBB was the result of a com-
bination of decreased L-carnitine transport into tissues and
decreased reabsorption in the kidneys.
As we have demonstrated previously, the preconditioning-
like cardioprotective effects of meldonium depend on a
decreased L-carnitine content in the heart tissues (Kuka et al.,
2012). In the present study, the time-dependent reduction in
L-carnitine content also correlated with the cardioprotective
effect induced by Methyl-GBB, although some significant dif-
ferences between the actions of Methyl-GBB and meldonium
were observed. After only 7 days of treatment, Methyl-GBB
reached the same maximal IS-limiting effect induced by mel-
donium, while after 14 days of treatment with Methyl-GBB,
the size of the infarcted area in the isolated heart model was
half that in the meldonium-treated hearts. The effect of
Methyl-GBB on limiting the IS was also confirmed in the in
vivo myocardial infarction model. As observed in isolated
hearts, the effects of limiting the IS induced by Methyl-GBB in
the in vivo model were almost twice the effects induced by
meldonium (Sesti et al., 2006). In addition, Methyl-GBB treat-
ment improved rat survival at 24 h after myocardial infarction
in vivo. The overall cardioprotective actions of Methyl-GBB
were greater than those of meldonium.
In previous studies, we have observed an increase in the
nuclear content of PPAR-α and PGC-1α, as a response to
decreased L-carnitine content (Liepinsh et al., 2011c; 2013b).
The compensatory changes in the expression of the genes
related to FAO and the redirection of LCFA flux from the
mitochondria to the peroxisomes are clearly beneficial to
preserve mitochondrial function and recovery after heart
ischaemia (Liepinsh et al., 2013b). In this study, we observed
that the decrease in L-carnitine content did not induce sub-
stantial changes in gene expression involved in LCFA
metabolism in normoxic hearts. Therefore, Methyl-GBB treat-
ment induced a decrease in L-carnitine availability, acylcar-
nitine production and reduced palmitate oxidation in
isolated mitochondria, peroxisomes, both in isolated hearts
and in vivo. In previous studies using isolated mitochondria
or cultured cells, palmitoylcarnitine, an intermediate in LCFA
metabolism, affected mitochondrial membrane potential, the
mitochondrial permeability transition pore, activity of the
respiratory chain and the generation of reactive oxygen
species (Abdul-Ghani et al., 2008; Tominaga et al., 2008;
Seifert et al., 2010). Therefore, the main advantage of the
pharmacological decrease of L-carnitine might be the reduc-
tion of direct damage by the long-chain acylcarnitines on
mitochondria in an ischaemic heart. In contrast, in reperfu-
Figure 7
Heart work [heart rate × left ventricular developed pressure (LVDP)]
(A) was measured in isolated hearts after 14 days of treatment by
meldonium (100 mg·kg−1) or Methyl-GBB (1, 5 and 20 mg·kg−1).
Heart function in vivo (B) was measured by echocardiography after
14 days of treatment by meldonium (100 mg·kg−1) or Methyl-GBB
(1, 5 and 20 mg·kg−1). Data shown are the means ± SEM of 5–10
animals.
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sion, the metabolism of LCFA in Methyl-GBB-treated hearts
was not decreased because the up-regulated PPARα/PGC-1α
pathway-dependent gene expression compensated for the
reduced L-carnitine content. Thus, while the protection
against long-chain acylcarnitine accumulation-induced
damage is beneficial in ischaemia, when the oxygen supply is
limited, the activation of LCFA metabolism in reperfusion
would help restore energy production in the heart.
Figure 8
Effects of meldonium (100 mg·kg−1) and Methyl-GBB (1, 5 and 20 mg·kg−1) on the infarct size after 14 days of treatment (A). Effects of Methyl-GBB
(5 mg·kg−1) on the infarct size after 3, 7 and 14 days of treatment (B). Effects of Methyl-GBB (20 mg·kg−1) treatment on ADP-stimulated
mitochondrial respiration (state 3) (C) and uncoupling of oxidative phosphorylation (state 4) (D) in cardiac fibres (expressed as mg tissue), isolated
after ischaemia-reperfusion . Myocardial infarction experiments were performed in the isolated rat hearts. Data shown are the means ± SEM of
at least 5–10 animals. *P < 0.05, significantly different from control group;< #P < 0.05, significantly different from meldonium group; Tukey’s test.
Figure 9
Effects of Methyl-GBB (10 and 20 mg·kg−1) on the AAR (A) infarct size (B) and rat 24 h survival (C). Methyl-GBB was administered daily for 14 days.
Data shown are the means ± SEM of at least eight animals. *P < 0.05, significantly different from control group; Tukey’s test.
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Enhanced glucose oxidation is beneficial during ischae-
mia because of the reduced proton production and less
oxygen consumed per ATP produced (Ussher et al., 2012). In
this study, we also observed that the decreased content of
long-chain acylcarnitines and LCFA oxidation by Methyl-
GBB treatment induced stimulation of glucose oxidation in
the heart. These results suggest that reduced IS is at least
partly associated with a stimulation of glucose and lactate
oxidation and related beneficial effects.
In conclusion, these results provide additional evidence
that the reduction of L-carnitine content by the inhibition of
OCTN2 represents an effective strategy to protect the heart
against ischaemia-reperfusion-induced damage. Methyl-GBB
treatment leads to cardioprotective effects and increased sur-
vival by limiting LCFA oxidation and facilitating glucose
metabolism.
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Figure S1 Effect of Methyl-GBB on OCTN2-mediated
L-carnitine transport in HEK293 cells. Each value represents
the mean ± SEM of three experiments. The experiment was
performed as described by Dambrova et al. (2013, doi:
10.1002/jcph.135).
Figure S2 Plasma concentrations of meldonium and Methyl-
GBB after 1, 3, 7 and 14 days of treatment with meldonium
(100 mg·kg−1) or Methyl-GBB (1, 5 and 20 mg·kg−1). Each value
represents the mean ± SEM of 5–10 animals.
Figure S3 Left ventricular developed pressure (a), heart rate
(b) and coronary flow (c) of isolated hearts after 14 days of
treatment by meldonium (100 mg·kg−1) and Methyl-GBB (1, 5
and 20 mg·kg−1). Each value represents the mean ± SEM of 10
animals.
BJPDecreased fatty acid oxidation is cardioprotective
British Journal of Pharmacology (2015) 172 1319–1332 1331
Figure S4 Dimensions of the left chamber of the heart (a)
and wall thickness (b) were measured by echocardiography
after 14 days of treatment with Methyl-GBB (20 mg·kg−1). The
mean values of left ventricular internal diameter in end dias-
tole (LVIDD), left ventricular internal diameter in end systole
(LVIDS), interventricular septum thickness in diastole (IVSd),
interventricular septum thickness in systole (IVSs), left ven-
tricular posterior wall thickness in diastole (LVPWd) and left
ventricular posterior wall thickness in systole (LVPWs) repre-
sent the mean ± SEM of five animals.
Table S1 Sequences of primers used for quantitative RT-PCR.
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